FAQ on NanoViricides, Inc.'s MPox Drug Progress and WHO's Global Health Emergency Extension

What is NanoViricides, Inc. announcing regarding MPox?

NanoViricides, Inc. is announcing the progress of its broad-spectrum antiviral drug NV-387 against MPox, following the WHO’s extension of the Public Health Emergency of International Concern (PHEIC), highlighting its completion of Phase I trials with a strong safety profile and advancement toward Phase II trials in Africa.

Why is NV-387 considered a potential breakthrough in treating MPox?

NV-387 is considered a potential breakthrough because it mimics human cell features to block viral entry, potentially avoiding resistance, unlike existing treatments such as tecovirimat and brincidofovir, which show limited efficacy or adverse effects.

How does NV-387 compare to existing MPox treatments?

NV-387 differs from existing treatments like tecovirimat and brincidofovir by mimicking human cell features to block viral entry, which may avoid the resistance and adverse effects associated with current options.

What are the next steps for NV-387 in its development?

The next step for NV-387 is advancing toward Phase II human clinical trials in Africa, as part of the company’s plan to address the global MPox threat and unlock multi-billion-dollar markets, including government bioterrorism stockpiles.

Who is involved in the development of NV-387?

NanoViricides, Inc., a clinical-stage pioneer in host-mimetic nanomedicine, is developing NV-387, with intellectual property, technology, and proprietary know-how from TheraCour Pharma, Inc., under a Memorandum of Understanding for antiviral infections.

Where can I find more information about NanoViricides, Inc. and NV-387?

More information about NanoViricides, Inc. and NV-387 can be found on the company’s website at www.NanoViricides.com and in the full press release at https://ibn.fm/ZHeZ6.

What implications does the WHO’s extension of the global health emergency have for NV-387?

The WHO’s extension of the global health emergency underscores the ongoing threat of MPox and the urgent need for effective treatments like NV-387, positioning NanoViricides, Inc. to potentially address a significant public health challenge and access substantial markets.

What other viruses is NV-387 being developed to treat?

NV-387 is being developed as a treatment for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, in addition to MPOX/Smallpox infections, showcasing its broad-spectrum antiviral potential.